Mark G. Kris
Impact in
- Oncology top 0.01%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 398
- Lung Cancer Diagnosis and Treatment 152
- Oncology 386
- Lung Cancer Research Studies 196
- Colorectal Cancer Treatments and Studies 65
- HER2/EGFR in Cancer Research 60
- Cancer Treatment and Pharmacology 41
- Co-authors
- Vincent A. Miller (99 shared papers)Gregory J. Riely (155 shared papers)William Pao (71 shared papers)Maureen F. Zakowski (53 shared papers)Marc Ladanyi (119 shared papers)Maria E. Arcila (79 shared papers)Valerie W. Rusch (80 shared papers)Harold Varmus (6 shared papers)
- Journals
- Journal of Clinical Oncology (210 papers)Journal of Thoracic Oncology (61 papers)Clinical Cancer Research (39 papers)Lung Cancer (37 papers)Cancer (31 papers)
- Partner nations
- United StatesJapanUnited Kingdom
In The Last Decade
Mark G. Kris
646 papers receiving 60.7k citations
Mark G. Kris's Hit Papers
Peers
Comparison fields: 5 of 178
- Oncology 36.3k
- Pulmonary and Respiratory Medicine 38.5k
- Cancer Research 9.4k
- Molecular Biology 16.7k
- Pathology and Forensic Medicine 3.6k
Countries citing papers authored by Mark G. Kris
This map shows the geographic impact of Mark G. Kris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Kris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Kris more than expected).
Fields of papers citing papers by Mark G. Kris
This network shows the impact of papers produced by Mark G. Kris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Kris. The network helps show where Mark G. Kris may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark G. Kris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 661 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Hit paper breakdown → | 2004 | 3487 |
| 2 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain Hit paper breakdown → | 2005 | 2792 |
| 3 | Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2003 | 2119 |
| 4 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers Hit paper breakdown → | 2013 | 1893 |
| 5 | Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial Hit paper breakdown → | 2015 | 1668 |
| 6 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Hit paper breakdown → | 2005 | 1228 |
| 7 | TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 1204 |
| 8 | Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Hit paper breakdown → | 2000 | 1124 |
| 9 | Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer Hit paper breakdown → | 1991 | 1109 |
| 10 | Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2011 | 827 |
| 11 | Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Hit paper breakdown → | 2011 | 757 |
| 12 | Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Hit paper breakdown → | 2000 | 665 |
| 13 | Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Hit paper breakdown → | 2006 | 664 |
| 14 | ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 646 |
| 15 | Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2009 | 644 |
| 16 | Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 628 |
| 17 | Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib Hit paper breakdown → | 2006 | 623 |
| 18 | Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Hit paper breakdown → | 1998 | 606 |
| 19 | Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis Hit paper breakdown → | 2014 | 601 |
| 20 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation Hit paper breakdown → | 2012 | 555 |
About Mark G. Kris
Mark G. Kris is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Surgery, having authored 661 papers that have together received 62.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (398 papers), Lung Cancer Research Studies (196 papers), Lung Cancer Diagnosis and Treatment (152 papers), Cancer Genomics and Diagnostics (83 papers), Colorectal Cancer Treatments and Studies (65 papers), HER2/EGFR in Cancer Research (60 papers), Nausea and vomiting management (58 papers) and Cancer Treatment and Pharmacology (41 papers). The work is most often cited by research in Oncology (36.3k citations), Pulmonary and Respiratory Medicine (38.5k citations), Cancer Research (9.4k citations), Molecular Biology (16.7k citations) and Pathology and Forensic Medicine (3.6k citations). Mark G. Kris has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Vincent A. Miller, Gregory J. Riely, William Pao, Maureen F. Zakowski, Marc Ladanyi, Maria E. Arcila, Valerie W. Rusch, Harold Varmus, Richard J. Gralla and Camelia S. Sima. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Cancer Research, Lung Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.